18 Sep 2017 --- Scientists at Rutgers University-New Brunswick in the US have found that getting rid of the enzyme known as phosphatidic acid phosphatase can increase the risk of cancer, diabetes, inflammation and other medical issues. Their findings were published online in the Journal of Biological Chemistry last month.
It was already known that the enzyme phosphatidic acid phosphatase plays a crucial role in regulating the amount of fat in the human body. Controlling it is therefore of interest in the fight against obesity, according to the Rutgers University press release.
“The goal of our lab is to understand how we can tweak and control this enzyme,” says George M. Carman, Board of Governors professor in the Department of Food Science in the School of Environmental and Biological Sciences. “For years, we have been trying to find out how to fine-tune the enzyme's activity so it's not too active and creating too much fat, but it's active enough to keep the body healthy.”
Study finds critical role for important enzyme Rutgers University reports that the enzyme was discovered in 1957 and Gil-Soo Han, research assistant professor in the Rutgers Center for Lipid Research, discovered the gene encoding the enzyme in 2006. The enzyme determines whether the body's phosphatidic acid will be used to create fat or create the lipids in cell membranes.
The study used baker's yeast as a model organism, since it also contains the key enzyme. Study lead author Han deleted a gene in yeast to eliminate the enzyme. That led to accumulations of phosphatidic acid, with cells making far more membrane lipids than necessary, says Carman, who founded the center in Rutgers’ New Jersey Institute for Food, Nutrition, and Health a decade ago.
“We have found that maybe a more critical role for the enzyme is to make sure that cells are not making too much membrane lipid,” Carman says. “If you make too much membrane lipid, you make too much membrane and the cells are permitted to grow uncontrollably, a condition characteristic of cancer.”
Since the discovery of the gene encoding the enzyme, people worldwide have studied the enzyme because of its relation to obesity, lipodystrophy, inflammation, diabetes and other conditions, Carman says.
Lately, the Rutgers scientists have been trying to understand the enzyme's structure and function. The next step is to figure out how to control it, Carman says.
“The key take-home message is that things have to be balanced,” according to Carman. “To keep the balance between making storage fat and membrane lipid, you have to have balanced diet.”
09 Apr 2018 –
Novartis has entered into an agreement and plan ...
02 Mar 2018 –
The commissioner of the US Food and Drug ...
02 Mar 2018 –
A research team has laid the foundation for a ...
23 Feb 2018 –
Consumers across EMEA want the food and beverage ...
29 Jan 2018 –
Johnson & Johnson has withdrawn from the ...